Hahn May Not Run Into Questions About Industry Ties Like His Predecessors
Executive Summary
Nominee for US FDA commissioner has remained largely focused on academic work and private practice, receiving only a few payments from pharma and device companies.
You may also be interested in...
Flagship's $3.37bn Fund To Grow First-In-Category Firms
Flagship, the investor behind COVID-19 success story Moderna, has raised a huge fund that will be used to create and develop its own companies before spinning them off.
Commissioner Nominee's Required Divestitures Illustrate US FDA's Broader Recruitment Challenge
Stephen Hahn will have over 100 stocks to divest upon becoming FDA commissioner.
US FDA Commissioner Nominee Hahn On Fast Track With 20 November Hearing
Stephen Hahn will go before the Senate health committee less than three weeks after being nominated. Pink Sheet's historical charts illustrate how a long wait and a quick hearing could mean a rapid confirmation.